Angelina Jolie has revealed why she thinks her six children with her ex-husband, Brad Pitt, won't follow in their famous ...

Hims & Hers Health (NYSE:HIMS) is gearing up to launch an off-patent version of Novo Nordisk's (NVO) (OTCPK:NONOF) older GLP-1 weight loss therapy liraglutide in 2025, CEO of the telehealth platform ...

A lovely photo of the wife of Baltasar Ebang Engonga, the Director General of the ANIF, has taken over social media as many ...

While Trump spent much of his nearly two-hour speech in Michigan ’s Grand Rapids hurling insults and profanities at his ...

Hims & Hers Health (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year ...

During the Vietnam War, thousands of people purchased bracelets with the names of soldiers who were missing in action during ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Hims & Hers Health, Inc. ( (HIMS) ) has released its Q3 earnings. Here is a breakdown of the information Hims & Hers Health, Inc.

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy ...

Reports Q3 revenue $401.6M, consensus $382.2M. “Improving momentum in both the Hims and Hers brands delivered another strong quarter of ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.